Top Markets
#1 MowCat MowCat +48.45%
#2 Bermuda Shorts Bermuda Shorts +31.49%
#3 Biconomy Biconomy +22.77%
#4 Velvet Velvet +21.04%
#5 Derive Derive +19.24%
#6 MarsCoin MarsCoin +17.75%
#7 Quack AI Quack AI +17.33%
#8 Audiera Audiera +14.23%
#9 Perle Perle +14.15%
#10 aPriori aPriori +13.82%
Coin of the day
MowCat MowCat
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Aeterna Zentaris Inc. Aeterna Zentaris Inc.

Aeterna Zentaris Inc.

AEZS
Classificação em ações #35469
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company,... Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone. Macimorelin is employed for diagnosing growth hormone deficiency in both adult and pediatric patients, and is also under investigation for various oncology indications. The drug is marketed commercially under the brand name Macrilen. The company engages in various licensing agreements, prominently with University Wuerzburg. This collaboration encompasses the research, development, manufacture, and commercialization of a prospective COVID-19 vaccine. It also involves developing, producing, and marketing a treatment for neuromyelitis optica spectrum disorder (NMOSD), establishing human 3D intestinal tissue models for infection biology research, and advancing pre-clinical work towards a potential Parkinson's disease therapy. Additionally, Aeterna Zentaris has formed licensing partnerships with Consilient Health Ltd., Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada. Another key collaboration is with The University of Sheffield in the United Kingdom, dedicated to the research, development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to treat primary hypoparathyroidism. Founded in 1990, Aeterna Zentaris Inc. maintains its corporate headquarters in Summerville, South Carolina.
Preço da ação
$3.97
Última sincronização: 2024-09-03
Valor de mercado
$3.86M
Variação (1 dia)
-1.00%
Variação (1 ano)
0.00%
País
US
Negociar Aeterna Zentaris Inc. (AEZS)

Categoria

Healthcare
Histórico de dividendos de Aeterna Zentaris Inc. (AEZS)
Aeterna Zentaris Inc. (símbolo da ação: AEZS) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Aeterna Zentaris Inc. (AEZS) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
29.00%
BE